家族史
外展
鉴定(生物学)
癌症登记处
医学
基因检测
癌症
指南
医学遗传学
语句(逻辑)
家庭医学
病史
遗传学
病理
内科学
生物
植物
政治学
基因
法学
作者
Vinit Singh,Thomas Rafter,Mohamad Sharbatji,Jing Liu,Quiana Brown,Karina L. Brierley,Claire M. Healy,Rosa M. Xicola,Nitu Kashyap,Xavier Llor
标识
DOI:10.1136/jmg-2025-110718
摘要
Background Despite well-established criteria for genetic testing to rule out hereditary cancer syndromes (HCSs), most pathogenic variant (PV) carriers are not being tested. Thus, mechanisms that allow for better identification and a streamlined process for testing need to be implemented. The main purpose was to develop a self-updating, guideline-driven tool integrated with the electronic health record (EHR) to prospectively identify at-risk individuals and facilitate outreach and diagnosis. Methods National Comprehensive Cancer Network/American College of Medical Genetics criteria for genetic testing were translated into three distinct rule-based conditional logic statements in the EHR from 218 rules that serially evaluate each aspect of individual criteria, which together roll up into a logic statement of ‘at-risk’. The rules evaluate personal or family history, determine age at onset and categorise family relationships. This tool is applied to a system-wide registry of active patients. Results Out of 1 325 545 individuals, 59 377 (4.48%) were identified as at-risk and thus constitute the At-Risk Cancer Genetic Syndrome Identification (ARCAGEN-ID) registry. Of those, only 12 377 (20.9%) had previously been evaluated, and 2506 had a PV. ARCAGEN-ID appropriately included 96.2% of cases. ARCAGEN-ID individuals not previously evaluated were more often included based on family history criteria (79.8% vs 49.3%), and less often because of both personal and family history of cancer (13% vs 41%) (p<0.001). Conclusions This study is the first to use an EHR-based registry for the automatic and prospective identification of individuals eligible for genetic testing based on current criteria for all major HCS. By streamlining the identification process, this approach has the potential to dramatically increase diagnostic rates and improve cancer-related survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI